Benzinga | May 25, 2021 07:02AM EDT

Morgan Stanley Initiates Coverage On Vaccitech with Overweight Rating, Announces Price Target of $22

Morgan Stanley analyst Matthew Harrison initiates coverage on Vaccitech (NASDAQ:VACC) with a Overweight rating and announces Price Target of $22.